These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33910930)

  • 1. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
    Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
    Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
    Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
    Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
    Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
    Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
    Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
    Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
    Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR.
    Al-Mayhani TF; Heywood RM; Vemireddy V; Lathia JD; Piccirillo SGM; Watts C
    Neuro Oncol; 2019 Jun; 21(6):719-729. PubMed ID: 30590711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
    Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
    Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
    Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical activity of the
    Makhlin I; Salinas RD; Zhang D; Jacob F; Ming GL; Song H; Saxena D; Dorsey JF; Nasrallah MP; Morrissette JJ; Binder ZA; O'Rourke DM; Desai AS; Brem S; Bagley SJ
    CNS Oncol; 2019 Nov; 8(3):CNS43. PubMed ID: 31769726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
    Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
    Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.